1-(1-苄基哌啶-4-基)-N-甲基甲胺 | 147908-88-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(1-苄基哌啶-4-基)-N-甲基甲胺
• 英文名称: benzyl-4-(methylaminomethyl)piperidine
• 英文别名: 1-(1-Benzylpiperidin-4-YL)-N-methylmethanamine
• CAS: 147908-88-1
• 化学式: C₁₄H₂₂N₂
• 分子量: 218.342
• InChiKey: ZCMNLHOSHQVDRP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  15.3
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 海关编码：
  2933399090
• WGK Germany：
  3
• 危险标志：
  GHS06
• 危险性描述：
  H301,H319
• 危险性防范说明：
  P301 + P310,P305 + P351 + P338

SDS

---

SECTION 1: Identification of the substance/mixture and of the company/undertaking
Product identifiers
Product name : 1-(1-Benzylpiperidin-4-Yl)-N-Methylmethanamine
: CBR01315
REACH No. : A registration number is not available for this substance as the substance
or its uses are exempted from registration, the annual tonnage does not
require a registration or the registration is envisaged for a later
registration deadline.

---

SECTION 2: Hazards identification
Classification of the substance or mixture
Classification according to Regulation (EC) No 1272/2008
Acute toxicity, Oral (Category 3), H301
Eye irritation (Category 2), H319
For the full text of the H-Statements mentioned in this Section, see Section 16.
Classification according to EU Directives 67/548/EEC or 1999/45/EC
T Toxic R25, R36
For the full text of the R-phrases mentioned in this Section, see Section 16.
Label elements
Labelling according Regulation (EC) No 1272/2008
Pictogram
Signal word Danger
Hazard statement(s)
Toxic if swallowed.
Causes serious eye irritation.
Precautionary statement(s)
P301 + P310 IF SWALLOWED: Immediately call a POISON CENTER or doctor/
physician.
P305 + P351 + P338 IF IN EYES: Rinse cautiously with water for several minutes. Remove
contact lenses, if present and easy to do. Continue rinsing.
Supplemental Hazard none
Statements
Other hazards
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

---

SECTION 3: Composition/information on ingredients
Substances
Molecular weight : 218,35 g/mol
Hazardous ingredients according to Regulation (EC) No 1272/2008
Component Classification Concentration
1-(1-Benzylpiperidin-4-Yl)-N-Methylmethanamine
Acute Tox. 3; Eye Irrit. 2; <= 100 %
H301, H319
Hazardous ingredients according to Directive 1999/45/EC
Component Classification Concentration
1-(1-Benzylpiperidin-4-Yl)-N-Methylmethanamine
T, R25 - R36 <= 100 %
For the full text of the H-Statements and R-Phrases mentioned in this Section, see Section 16

---

SECTION 4: First aid measures
Description of first aid measures
General advice
Consult a physician. Show this safety data sheet to the doctor in attendance.
If inhaled
If breathed in, move person into fresh air. If not breathing, give artificial respiration. Consult a physician.
In case of skin contact
Wash off with soap and plenty of water. Take victim immediately to hospital. Consult a physician.
In case of eye contact
Rinse thoroughly with plenty of water for at least 15 minutes and consult a physician.
If swallowed
Never give anything by mouth to an unconscious person. Rinse mouth with water. Consult a physician.
Most important symptoms and effects, both acute and delayed
The most important known symptoms and effects are described in the labelling (see section 2.2) and/or in
section 11
Indication of any immediate medical attention and special treatment needed
No data available

---

SECTION 5: Firefighting measures
Extinguishing media
Suitable extinguishing media
Use water spray, alcohol-resistant foam, dry chemical or carbon dioxide.
Special hazards arising from the substance or mixture
Nature of decomposition products not known.
Advice for firefighters
Wear self-contained breathing apparatus for firefighting if necessary.
Further information
No data available

---

SECTION 6: Accidental release measures
Personal precautions, protective equipment and emergency procedures
Wear respiratory protection. Avoid dust formation. Avoid breathing vapours, mist or gas. Ensure
adequate ventilation. Evacuate personnel to safe areas. Avoid breathing dust.
For personal protection see section 8.
Environmental precautions
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.
Methods and materials for containment and cleaning up
Pick up and arrange disposal without creating dust. Sweep up and shovel. Keep in suitable, closed
containers for disposal.
Reference to other sections
For disposal see section 13.

---

SECTION 7: Handling and storage
Precautions for safe handling
Avoid contact with skin and eyes. Avoid formation of dust and aerosols.
Provide appropriate exhaust ventilation at places where dust is formed.
For precautions see section 2.2.
Conditions for safe storage, including any incompatibilities
Store in cool place. Keep container tightly closed in a dry and well-ventilated place.
Storage class (TRGS 510): Non-combustible, acute toxic Cat.3 / toxic hazardous materials or hazardous
materials causing chronic effects
Specific end use(s)
Apart from the uses mentioned in section 1.2 no other specific uses are stipulated

---

SECTION 8: Exposure controls/personal protection
Control parameters
Components with workplace control parameters
Exposure controls
Appropriate engineering controls
Avoid contact with skin, eyes and clothing. Wash hands before breaks and immediately after handling
the product.
Personal protective equipment
Eye/face protection
Face shield and safety glasses Use equipment for eye protection tested and approved under
appropriate government standards such as NIOSH (US) or EN 166(EU).
Skin protection
Handle with gloves. Gloves must be inspected prior to use. Use proper glove removal technique
(without touching glove's outer surface) to avoid skin contact with this product. Dispose of
contaminated gloves after use in accordance with applicable laws and good laboratory practices.
Wash and dry hands.
The selected protective gloves have to satisfy the specifications of EU Directive 89/686/EEC and
the standard EN 374 derived from it.
Body Protection
Complete suit protecting against chemicals, The type of protective equipment must be selected
according to the concentration and amount of the dangerous substance at the specific workplace.
Respiratory protection
Where risk assessment shows air-purifying respirators are appropriate use a full-face particle
respirator type N99 (US) or type P2 (EN 143) respirator cartridges as a backup to engineering
controls. If the respirator is the sole means of protection, use a full-face supplied air respirator. Use
respirators and components tested and approved under appropriate government standards such
as NIOSH (US) or CEN (EU).
Control of environmental exposure
Prevent further leakage or spillage if safe to do so. Do not let product enter drains.

---

SECTION 9: Physical and chemical properties
Information on basic physical and chemical properties
a) Appearance Form: solid
b) Odour No data available
c) Odour Threshold No data available
d) pH No data available
e) Melting point/freezing No data available
point
f) Initial boiling point and No data available
boiling range
g) Flash point No data available
h) Evaporation rate No data available
i) Flammability (solid, gas) No data available
j) Upper/lower No data available
flammability or
explosive limits
k) Vapour pressure No data available
l) Vapour density No data available
m) Relative density No data available
n) Water solubility No data available
o) Partition coefficient: n- No data available
octanol/water
p) Auto-ignition No data available
temperature
q) Decomposition No data available
temperature
r) Viscosity No data available
s) Explosive properties No data available
t) Oxidizing properties No data available
Other safety information
No data available

---

SECTION 10: Stability and reactivity
Reactivity
No data available
Chemical stability
Stable under recommended storage conditions.
Possibility of hazardous reactions
No data available
Conditions to avoid
No data available
Incompatible materials
Strong oxidizing agents
Hazardous decomposition products
In the event of fire: see section 5

---

SECTION 11: Toxicological information
Information on toxicological effects
Acute toxicity
No data available
Skin corrosion/irritation
No data available
Serious eye damage/eye irritation
No data available
Respiratory or skin sensitisation
No data available
Germ cell mutagenicity
No data available
Carcinogenicity
IARC: No component of this product present at levels greater than or equal to 0.1% is identified as
probable, possible or confirmed human carcinogen by IARC.
Reproductive toxicity
No data available
Specific target organ toxicity - single exposure
No data available
Specific target organ toxicity - repeated exposure
No data available
Aspiration hazard
No data available
Additional Information
RTECS: Not available
To the best of our knowledge, the chemical, physical, and toxicological properties have not been
thoroughly investigated.

---

SECTION 12: Ecological information
Toxicity
No data available
Persistence and degradability
No data available
Bioaccumulative potential
No data available
Mobility in soil
No data available
Results of PBT and vPvB assessment
This substance/mixture contains no components considered to be either persistent, bioaccumulative and
toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.
Other adverse effects
No data available

---

SECTION 13: Disposal considerations
Waste treatment methods
Product
Offer surplus and non-recyclable solutions to a licensed disposal company. Dissolve or mix the material
with a combustible solvent and burn in a chemical incinerator equipped with an afterburner and scrubber.
Contaminated packaging
Dispose of as unused product.

---

SECTION 14: Transport information
UN number
ADR/RID: 2811 IMDG: 2811 IATA: 2811
UN proper shipping name
ADR/RID: TOXIC SOLID, ORGANIC, N.O.S. (1-(1-Benzylpiperidin-4-Yl)-N-Methylmethanamine)
IMDG: TOXIC SOLID, ORGANIC, N.O.S. (1-(1-Benzylpiperidin-4-Yl)-N-Methylmethanamine)
IATA: Toxic solid, organic, n.o.s. (1-(1-Benzylpiperidin-4-Yl)-N-Methylmethanamine)
Transport hazard class(es)
ADR/RID: 6.1 IMDG: 6.1 IATA: 6.1
Packaging group
ADR/RID: III IMDG: III IATA: III
Environmental hazards
ADR/RID: no IMDG Marine pollutant: no IATA: no
Special precautions for user
No data available

---

SECTION 15: Regulatory information
This safety datasheet complies with the requirements of Regulation (EC) No. 1907/2006.
Safety, health and environmental regulations/legislation specific for the substance or mixture
No data available
Chemical Safety Assessment
T Toxic
R25 Toxic if swallowed.
R36 Irritating to eyes.
Further information
only.
The above information is believed to be correct but does not purport to be all inclusive and shall be
used only as a guide. The information in this document is based on the present state of our knowledge
and is applicable to the product with regard to appropriate safety precautions. It does not represent any

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(1-苄基哌啶-4-基)-N-甲基甲胺 、 4'-氟-4-碘苯丁酮 在 potassium carbonate 作用下， 以 丙酮 为溶剂， 以77%的产率得到1-benzyl-4-{N-methyl-N-[4-(p-fluorophenyl)-4-oxobutyl]aminomethyl}piperidine
  参考文献：
  名称：

  N-(isoquinolin-5-ylsulphonyl) azacycloalkanes

  摘要：

  式(I)的化合物：##STR1## 其中R.sub.1、R.sub.2、U、X、Y、Z、n、m、p和r的定义如说明中所述，以及含有相同化合物的药物。

  公开号：

  US05298503A1

文献信息

• [EN] 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS<br/>[FR] 4-ARYLOXYQUINOLIN-2(1H)-ONES UTILES EN TANT QU'INHIBITEURS DE LA KINASE MTOR ET DE LA KINASE PI3, DEVANT SERVIR EN TANT QU'AGENTS ANTICANCÉREUX
  申请人：WYETH LLC

  公开号：WO2010030967A1

  公开（公告）日：2010-03-18

  4-aryloxyquinolin-2(1H)-ones as mtor kinase and PI3 kinase inhibitors, for use as anti-cancer agents. Compounds of the formula I and pharmaceutically acceptable salts thereof, wherein A, B, R1, R2, R3, R4, R5, R6, and R7 are defined as set forth herein are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds of the invention and a pharmaceutically acceptable carrier, methods of making the compounds of the invention and methods of using the compounds for inhibiting mTOR and PI3 kinases and for treating cancers.

  4-芳氧基喹啉-2(1H)-酮作为mTOR激酶和PI3激酶抑制剂，用作抗癌药物。公开了具有以下式I及其药学上可接受的盐的化合物，其中A、B、R1、R2、R3、R4、R5、R6和R7的定义如本文所述。还公开了包括该发明化合物和药学上可接受的载体的药物组合物，制备该发明化合物的方法以及使用该化合物抑制mTOR和PI3激酶并治疗癌症的方法。
• Piperidine-4 sulphonamide compounds
  申请人：——

  公开号：US20010034352A1

  公开（公告）日：2001-10-25

  Compound of formula (I): 1 wherein: R 1 represents hydrogen or alkyl, R 2a and R 2b represent a group selected from hydrogen, halogen, alkyl, hydroxy, alkoxy, trihaloalkyl, cyano, nitro, amino, alkylamino and dialkylamino, R 3 represents hydrogen or hydroxy, X represents oxygen or methylene, V represents an alkylene chain that is optionally unsaturated and optionally substituted, U represents a bond or an alkylene chain, W represents a group selected from aryl and heteroaryl, each of those groups being optionally substituted by one or more identical or different groups, its isomers, its hydrates, its solvates and addition salts thereof with a pharmaceutically acceptable acid. Medicinal products containing the same which are useful in the treatment of diseases or pathological conditions in which endothelial dysfunction is known.

  化合物的结构式（I）如下所示： R1代表氢原子或烷基， R2a和R2b代表从氢、卤素、烷基、羟基、烷氧基、三卤代烷基、氰基、硝基、氨基、烷基氨基和二烷基氨基中选择的基团， R3代表氢原子或羟基， X代表氧原子或亚甲基， V代表一种可以是不饱和和可以被取代的烷基链， U代表键或烷基链， W代表从芳基和杂环芳基中选择的基团，每个基团可以被一个或多个相同或不同的基团取代， 它的异构体、水合物、溶剂合物以及与药学上可接受的酸形成的加合物。 含有这种化合物的药品对治疗已知存在内皮功能障碍的疾病或病理情况有用。
• 4-ARYLOXYQUINOLIN-2(1H)-ONES AS MTOR KINASE AND PI3 KINASE INHIBITORS, FOR USE AS ANTI-CANCER AGENTS
  申请人：Tsou Hwei-Ru

  公开号：US20100068204A1

  公开（公告）日：2010-03-18

  Compounds of the formula I and pharmaceutically acceptable salts thereof, wherein A, B, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , and R 7 are defined as set forth herein are disclosed. Also disclosed are pharmaceutical compositions comprising the compounds of the invention and a pharmaceutically acceptable carrier, methods of making the compounds of the invention and methods of using the compounds for inhibiting mTOR and PI3 kinases and for treating cancers.

  本文披露了化学式I及其药学上可接受的盐的化合物，其中A、B、R1、R2、R3、R4、R5、R6和R7的定义如本文所述。本文还披露了包含本发明化合物和药学上可接受的载体的制药组合物，制备本发明化合物的方法以及使用本化合物抑制mTOR和PI3激酶并治疗癌症的方法。
• SONIC HEDGEHOG MODULATORS
  申请人：MASSACHUSETTS INSTITUTE OF TECHNOLOGY

  公开号：US20160046590A1

  公开（公告）日：2016-02-18

  Sonic Hedgehog modulators and methods of use thereof are provided for.

  提供了刺猬Sonic Hedgehog调节剂及其使用方法。
• A highly selective purine-based inhibitor of CSF1R potently inhibits osteoclast differentiation
  作者：Thomas Ihle Aarhus、Jan Eickhoff、Bert Klebl、Anke Unger、Joanna Boros、Axel Choidas、Mia-Lisa Zischinsky、Camilla Wolowczyk、Geir Bjørkøy、Eirik Sundby、Bård Helge Hoff

  DOI：10.1016/j.ejmech.2023.115344

  日期：2023.7

  number of potent and highly selective purine-based inhibitors of CSF1R. The optimized 6,8-disubstituted antagonist, compound 9, has enzymatic IC50 of 0.2 nM, and displays a strong affinity toward the autoinhibited form of CSF1R, contrasting that of other previously reported inhibitors. As a result of its binding mode, the inhibitor shows excellent selectivity (Selectivity score: 0.06), evidenced by

  集落刺激因子 1 受体 (CSF1R) 在许多炎症过程的调节中起着重要作用，激酶的过度表达与多种疾病状态有关。识别 CSF1R 的选择性小分子抑制剂可能是治疗这些疾病的关键一步。通过建模、合成和系统的结构-活性关系研究，我们已经确定了许多有效且高度选择性的基于嘌呤的 CSF1R 抑制剂。优化的 6,8-二取代拮抗剂化合物9具有酶促 IC 500.2 nM，并显示出对 CSF1R 的自抑制形式的强亲和力，与其他先前报道的抑制剂形成对比。由于其结合模式，该抑制剂显示出出色的选择性（选择性得分：0.06），通过对一组 468 种激酶的分析证明。在基于细胞的测定中，该抑制剂显示剂量依赖性地阻断小鼠骨髓源性巨噬细胞中 CSF1 介导的下游信号传导（IC 50  = 106 nM）以及纳摩尔水平的破骨细胞分化破坏。然而，体内实验表明，为了进一步推进此类化合物，需要提高代谢稳定性。